Second cancers discovered by 18FDG PET/CT imaging for choroidal melanoma

Optometry

Volumn 78, Issue 8, 2007, Pages 396-401

  Chin, Kimberly ^a   Finger, Paul T ^a,b,c,d   Kurli, Madhavi ^a,b   Tena, Lawrence B ^d   Reddy, Shantan ^c  

^a NEW YORK EYE CANCER CENTER   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

18 fluorine labeled 2 deoxy 2 fluoro D glucose; Cancer; Choroidal; Imaging; Melanoma; Positron emission tomography computed tomography; Staging; Uveal

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BIOPSY; BREAST TUMOR; CANCER STAGING; CASE REPORT; CHOROID TUMOR; COLON TUMOR; DIFFERENTIAL DIAGNOSIS; FATALITY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MALE; MELANOMA; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING; SECOND CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BREAST NEOPLASMS; CHOROID NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SIGMOID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34447639966     PISSN: 15291839     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.optm.2007.03.013     Document Type: Article

References (24)

1. Diener-West M., Reynolds S.M., Agugliaro D.J., et al. Collaborative Ocular Melanoma Study Group Report 23. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 22 12 (2004) 2438-2444
2. Finger P.T. Do you speak ocular tumor?. Ophthalmology 110 1 (2003) 13-14
3. th ed. (2002), Springer, New York 347-384
4. Alcantara P., Hanlon A., Buyyounouski M.K., et al. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 109 1 (2007) 41-47
5. Al-azawi D., Kelly G., Myers E., et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 6 (2006) 220
6. Kapoor V., McCook B.M., and Torok F.S. An Introduction to PET-CT Imaging. Radiographics 24 (2004) 523-543
7. Lindholm P., Minn H., Leskinen-Kallio S., et al. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med 34 (1993) 1-6
8. Phelps M.E. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 41 (2000) 661-681
9. Egan K.M., Seddon J.M., Glynn R.J., et al. Epidemiological aspects of uveal melanoma. Surv Ophthalmol 32 (1988) 239-251
10. Finger P.T., Kurli M., Wesley P., et al. Whole body PET/CT imaging for detection of metastatic choroidal melanoma. Br J Ophthalmol 88 (2004) 1095-1097
11. Reddy S., Kurli M., Tena L.B., et al. PET/CT imaging: detection of choroidal melanoma. Br J Ophthalmol 89 10 (2005) 1265-1269
12. Finger P.T., Kurli M., Reddy S., et al. Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 89 10 (2005) 1270-1274
13. Finger P.T., Chin K., and Iacob C. 18FDG PET/CT SUV: A noninvasive biomarker for the risk of metastasis from choroidal melanoma. Br J Ophthalmol 113 (2006) 1854-1858
14. Freudenberg L.S., Schueler A.O., Beyer T., et al. Whole body fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. Surv Ophthalmol 49 (2004) 537-540
15. Roe R.H., Finger P.T., Kurli M., et al. whole-body positron emission tomography/computed tomography imaging and staging of orbital lymphoma. Ophthalmology 113 10 (2006) 1854-1858
16. Chan-Kai B.T., and Yen M.T. Combined positron emission tomography/computed tomography imaging of orbital lymphoma. Am J Ophthalmol 140 3 (2005) 531-533
17. van Leeuwen F.E., Klokman W.J., Stovall M., et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 (2003) 971-980
18. Obedian E., Fischer D.B., and Haffty B.G. Second malignancies after treatment of early stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 18 (2000) 2406-2412
19. Keller S.M., Vangel M.G., Wagner H., et al. Second primary tumors following adjuvant therapy of resected stages II and IIa non-small cell lung cancer. Lung Cancer 42 (2003) 79-86
20. Diener-West M., Reynolds S.M., Agugliaro D.J., and Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 123 12 (2005) 639-643
21. Choi J.Y., Lee K.S., Kwon O.J., et al. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol 23 30 (2005) 7654-7659
22. Collaborative Ocular Melanoma Study Group. Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma. Arch Ophthalmol 123 (2005) 601-604
23. th ed. (2003), BC Decker, Hamilton, Ontario 2623-2631
24. Dong C., and Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958-1996. Int J Cancer 93 (2001) 155-161